NL-OMON20629Other不适用
Evaluation of 18F-FDHT PET/CT as a predictor of response in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.
适应症
试验速览
- 阶段
- 不适用
- 状态
- Other
- 入组人数
- 60
研究概览
简要总结
/A
研究设计
- 研究类型
- Observational
入排标准
入选标准
- •Main inclusion criteria:
- •1. Age 50 or older.
排除标准
- •Main exclusion criteria:
- •1. Severe concurrent disease, infection, or co-morbidity that, in the judgment of the investigator, would make the patient inappropriate for enrollment.
研究者
相似试验
已完成
3 期
Evaluation of 18F-FDHT PET/CT as a predictor of response in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.10027476Prostate cancerNL-OMON41464niversitair Medisch Centrum Groningen60
进行中（未招募）
不适用
Evaluation of 18F-FDHT PET/CT as an early treatment response marker in patients with metastasized castration-resistant prostate cancer to be treated with enzalutamide.Castration-resistant prostate cancerEUCTR2012-005431-86-NLniversity Medical Center Groningen
进行中（未招募）
1 期
Study to see if new research scans can show how treatment affects the blood supply to kidney cancersPrimary and metastatic cancer. The active substance is a diagnostic agent that identifies angiogenesis associated with tumour growth.MedDRA version: 14.1 Level: PT Classification code 10050018 Term: Renal cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1 Level: PT Classification code 10038389 Term: Renal cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-002833-20-GBOxford University Hospitals NHS Trust10
已完成
不适用
Interest of PET/CT at 18F-FDG in the Post-therapeutic Management of Cervical CancerCervical CancerNCT04008095University Hospital, Brest40
已完成
不适用
Early response evaluation with 18F-FDG PET/CT and immunological profiling of circulating immune cells and tumor-draining lymph nodes in non-small cell lung cancer patients treated with immunotherapy.lung cancerNL-OMON48669Antoni van Leeuwenhoek Ziekenhuis50